By Steve Moore | Thursday 27 January 2022
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Describing itself as “a leading medical devices company in the field of regenerative medicine” Tissue Regenix (TRX) has made a full-year trading update headlined “Return to double digit growth in 2021” and concluding “the company has delivered robust financial and operational performance”. Why then are the shares still below 0.50p, compared to above 1.2p in May 2020?…